Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with prediabetes and obesity, preventing most from developing the disease over 176 weeks | iPharmaCenter

Pfizer decides to continue development of GLP agonist Danuglipron | iPharmaCenter